|
|
China's pharmaceutical sector has maintained steady growth over the past few years. Last
year, total revenues increased by nearly 26%, moving to $54.6 billion (437.3 billion RMB).
Changes in the competitive landscape, notably China's entry into the World Trade Organization (WTO) in 2001 and the development of a regulatory system through the establishment of China's State Drug Administration (SDA, now called the SFDA), are fueling the growth of contract manufacturing and contract research. Also driving this growth are the hai gui, Chinese nationals who return to China after gaining professional experience in Western biopharmaceutical companies.
|
|
In the nascent, but rapidly growing field of stem cell therapies, products are a long way from being commercialized. However, the market potential for stem cell therapies products is very large. This report aims to identify those technologies and opportunities in the United States with the greatest future opportunities, the opportunities to develop enabling technologies in the field, and the organizations and laboratories performing current research. In addition, a section is included that covers the legislative, political and social issues surrounding stem cell technology and research. These issues are impacting the development of the technology. |
By 2008, nearly half of all biopharmaceutical manufacturers may contract out production of biologics. Currently, 35% of biomanufacturers outsource at least some of their biologics production in mammalian, microbial, yeast, plant, or insect systems. These manufacturers project that by 2008, this number will increase, and 47% will outsource at least some production. |
|
|
